Mechanisms contributing to adverse outcomes of COVID-19 in obesity.
Mol Cell Biochem
; 477(4): 1155-1193, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1653634
ABSTRACT
A growing amount of epidemiological data from multiple countries indicate an increased prevalence of obesity, more importantly central obesity, among hospitalized subjects with COVID-19. This suggests that obesity is a major factor contributing to adverse outcome of the disease. As it is a metabolic disorder with dysregulated immune and endocrine function, it is logical that dysfunctional metabolism contributes to the mechanisms behind obesity being a risk factor for adverse outcome in COVID-19. Emerging data suggest that in obese subjects, (a) the molecular mechanisms of viral entry and spread mediated through ACE2 receptor, a multifunctional host cell protein which links to cellular homeostasis mechanisms, are affected. This includes perturbation of the physiological renin-angiotensin system pathway causing pro-inflammatory and pro-thrombotic challenges (b) existent metabolic overload and ER stress-induced UPR pathway make obese subjects vulnerable to severe COVID-19, (c) host cell response is altered involving reprogramming of metabolism and epigenetic mechanisms involving microRNAs in line with changes in obesity, and (d) adiposopathy with altered endocrine, adipokine, and cytokine profile contributes to altered immune cell metabolism, systemic inflammation, and vascular endothelial dysfunction, exacerbating COVID-19 pathology. In this review, we have examined the available literature on the underlying mechanisms contributing to obesity being a risk for adverse outcome in COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Body Mass Index
/
Intra-Abdominal Fat
/
Adiposity
/
COVID-19
/
Obesity
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Mol Cell Biochem
Year:
2022
Document Type:
Article
Affiliation country:
S11010-022-04356-w
Similar
MEDLINE
...
LILACS
LIS